Boehringer Ingelheim has entered a multi-year strategic partnership with Tempus AI to leverage its real-world data and artificial intelligence platform for oncology pipeline expansion. Through this collaboration, the German pharmaceutical company gains access to Tempus' de-identified patient data and its advanced analytics platform, Lens.

"Leveraging real-world patient data is crucial for strengthening our data foundation and harnessing advanced AI methodologies, ultimately accelerating drug development," said Jan Nygaard Jensen, head of computational innovation at the German drugmaker. "Integrating these comprehensive datasets with our internal data and techniques not only drives innovation but also enhances the precision and efficiency of pharmaceutical research, paving the way for groundbreaking medical advancements."

The partnership provides Boehringer with access to Tempus' extensive database, which contains over 8 million research records. Tempus' AI-enabled Lens platform allows researchers to define specific patient cohorts using molecular and clinical filters, or alternatively, to automatically build cohorts through Tempus One, an AI assistant that applies inclusion and exclusion criteria to patient data. Scientists can visualize or download these datasets for comprehensive analysis.

These data-driven insights will support various research initiatives, including biomarker discovery, patient stratification, novel target identification, development of combination therapy hypotheses, and patient education materials.

Boehringer Ingelheim's current oncology portfolio includes established treatments such as Gilotrif (afatinib) and Ofev (nintedanib) for non-small-cell lung cancer (NSCLC), as well as Tevimbra (tislelizumab) for esophageal and gastric cancers. The company is also advancing several investigational agents through its pipeline, including:

• Anti-DLL3 T-cell engager BI 764532 in Phase II trials for small-cell lung cancer and neuroendocrine cancers

• HER2 inhibitor zongertinib in Phase III testing for NSCLC

• MDM2-p53 antagonist brigimadlin in Phase III for liposarcoma

Additional early-stage assets targeting various solid tumors are also under development.

Mark Paul Petronczki, head of oncology research at Boehringer Ingelheim, explained the value of this partnership: "By combining internal, pre-clinical experimental data, with real-world data from Tempus on its AI-powered platform, we can profoundly deepen our understanding of cancer biology and accelerate our drug discovery and development efforts."